BOLOGNA, Italy I July 28, 2025 I Alfasigma S.p.A today announced positive topline results from the OLINGUITO Phase 3 clinical trial (NCT05785611; Eudra CT ...

LONDON, UK I July 28, 2025 I GSK plc (LSE/NYSE: GSK) today announced it has entered into agreements with Hengrui Pharma (600276.SH; 01276.HK) to develop up to ...

NEW ORLEANS, LA, USA I July 28, 2025 I South Rampart Pharma, Inc., a clinical-stage biopharmaceutical company focused on innovative non-opioid pain therapies, ...

Up to three development programs per year leading to a potential total deal value exceeding $1 billion contingent on milestone achievements.

COPENHAGEN, Denmark I July 28, 2025 I Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has approved ...

HONG KONG, China I July 28, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the National Medical Products Administration ...

Trontinemab’s Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative ...

JIANGSU, China I July 27, 2025 I Hengrui Pharma (600276.SH; 01276.HK) today announced it has entered into agreements with GSK plc (LSE/NYSE: GSK) to develop ...

DAEJEON, South Korea I July 28, 2025 I Alteogen Inc. (KOSDAQ:196170) announced today that the European Medicines Agency's (EMA) Committee for Medicinal ...

STUTTGART, Germany I July 27, 2025 I La Merie Publishing released its newest product entitled: Fibroblast Activation Protein (FAP) Targeted Therapy: a ...

BASEL, Switzerland I July 25, 2025 I Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the ...

HONG KONG, China I July 23, 2025 I Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) is pleased to announce that the first patient has been enrolled in the pivotal/registration Phase III clinical trial ...